1. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics
- Author
-
Luc Rochette, Eve Rigal, Marianne Zeller, Gabriel Malka, Yves Cottin, Catherine Vergely, Alexandre Meloux, Physiopathologie et épidémiologie cérébro-cardiovasculaire [Dijon] (PEC2), and Université de Bourgogne (UB)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Endocrinology, Diabetes and Metabolism ,Osteoporosis ,030209 endocrinology & metabolism ,Inflammation ,Bone and Bones ,Bone remodeling ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Osteoprotegerin ,medicine ,Animals ,Humans ,Orthopedics and Sports Medicine ,Vascular Calcification ,Receptor ,ComputingMilieux_MISCELLANEOUS ,biology ,business.industry ,Therapies, Investigational ,medicine.disease ,3. Good health ,Cardiovascular Diseases ,RANKL ,Cancer research ,biology.protein ,Tumor necrosis factor alpha ,Bone Remodeling ,030101 anatomy & morphology ,medicine.symptom ,business ,Signal Transduction ,Calcification - Abstract
Osteoporosis (OP) and cardiovascular diseases (CVD) are both important causes of mortality and morbidity in aging patients. There are common mechanisms underlying the regulation of bone remodeling and the development of smooth muscle calcification; a temporal relationship exists between osteoporosis and the imbalance of mineral metabolism in the vessels. Vascular calcification appears regulated by mechanisms that include both inductive and inhibitory processes. Multiple factors are implicated in both bone and vascular metabolism. Among these factors, the superfamily of tumor necrosis factor (TNF) receptors including osteoprotegerin (OPG) and its ligands has been established. OPG is a soluble decoy receptor for receptor activator of nuclear factor-kB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). OPG binds to RANKL and TRAIL, and inhibits the association with their receptors, which have been labeled as the receptor activator of NF-kB (RANK). Sustained release of OPG from vascular endothelial cells (ECs) has been demonstrated in response to inflammatory proteins and cytokines, suggesting that OPG/RANKL/RANK system plays a modulatory role in vascular injury and inflammation. For the development of potential therapeutic strategies targeting vascular calcification, critical consideration of the implications for bone metabolism must be taken into account to prevent potentially detrimental effects to bone metabolism.
- Published
- 2019